Literature DB >> 26359242

Unchained melody: revisiting the estimation of SF-6D values.

Benjamin M Craig1,2.   

Abstract

PURPOSE: In the original SF-6D valuation study, the analytical design inherited conventions that detrimentally affected its ability to predict values on a quality-adjusted life year (QALY) scale. Our objective is to estimate UK values for SF-6D states using the original data and multi-attribute utility (MAU) regression after addressing its limitations and to compare the revised SF-6D and EQ-5D value predictions.
METHODS: Using the unaltered data (611 respondents, 3503 SG responses), the parameters of the original MAU model were re-estimated under three alternative error specifications, known as the instant, episodic, and angular random utility models. Value predictions on a QALY scale were compared to EQ-5D3L predictions using the 1996 Health Survey for England.
RESULTS: Contrary to the original results, the revised SF-6D value predictions range below 0 QALYs (i.e., worse than death) and agree largely with EQ-5D predictions after adjusting for scale. Although a QALY is defined as a year in optimal health, the SF-6D sets a higher standard for optimal health than the EQ-5D-3L; therefore, it has larger units on a QALY scale by construction (20.9 % more).
CONCLUSIONS: Much of the debate in health valuation has focused on differences between preference elicitation tasks, sampling, and instruments. After correcting errant econometric practices and adjusting for differences in QALY scale between the EQ-5D and SF-6D values, the revised predictions demonstrate convergent validity, making them more suitable for UK economic evaluations compared to original estimates.

Entities:  

Keywords:  EQ-5D; Quality of life; SF-6D; Time trade-off; UK

Mesh:

Year:  2015        PMID: 26359242      PMCID: PMC4786460          DOI: 10.1007/s10198-015-0727-4

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  23 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

2.  Estimating an EQ-5D population value set: the case of Japan.

Authors:  Aki Tsuchiya; Shunya Ikeda; Naoki Ikegami; Shuzo Nishimura; Ikuro Sakai; Takashi Fukuda; Chisato Hamashima; Akinori Hisashige; Makoto Tamura
Journal:  Health Econ       Date:  2002-06       Impact factor: 3.046

3.  Deriving a preference-based single index from the UK SF-36 Health Survey.

Authors:  J Brazier; T Usherwood; R Harper; K Thomas
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.

Authors:  David G T Whitehurst; Richard Norman; John E Brazier; Rosalie Viney
Journal:  Value Health       Date:  2014-05-14       Impact factor: 5.725

5.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

6.  US valuation of the SF-6D.

Authors:  Benjamin M Craig; A Simon Pickard; Elly Stolk; John E Brazier
Journal:  Med Decis Making       Date:  2013-04-29       Impact factor: 2.583

7.  Non-monotonicity in the episodic random utility model.

Authors:  Nicolas A Menzies; Joshua A Salomon
Journal:  Health Econ       Date:  2010-11-18       Impact factor: 3.046

8.  Deriving distributional weights for QALYs through discrete choice experiments.

Authors:  Emily Lancsar; John Wildman; Cam Donaldson; Mandy Ryan; Rachel Baker
Journal:  J Health Econ       Date:  2011-01-17       Impact factor: 3.883

9.  A comparison of the EQ-5D and SF-6D across seven patient groups.

Authors:  John Brazier; Jennifer Roberts; Aki Tsuchiya; Jan Busschbach
Journal:  Health Econ       Date:  2004-09       Impact factor: 3.046

10.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655

View more
  1 in total

1.  US valuation of the SF-6D.

Authors:  Benjamin M Craig; A Simon Pickard; Elly Stolk; John E Brazier
Journal:  Med Decis Making       Date:  2013-04-29       Impact factor: 2.583

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.